In comparison to the control group, the AD-No PS group exhibited higher levels of AS (p < 0.04), T-tau (p < 0.0001), and p-tau181 (p < 0.0001); higher ratios of T-tau/Aβ42 (p < 0.0001) and p-tau181/Aβ42 (p < 0.0001); lower levels of Aβ42 (p < 0.0001); and a lower AS/p-tau181 ratio (p < 0.001). The gene discussed is MAPT; the disease is Alzheimer disease.